Topics

FDA approves GSK’s Nucala for young children with severe eosinophilic asthma

03:08 EDT 13 Sep 2019 | Pharmaceutical Business Review

Nucala is claimed to be the only targeted biologic to secure approval for the condition in the six to 11-year age group in the US. The FDA approval

The post FDA approves GSK’s Nucala for young children with severe eosinophilic asthma appeared first on Pharmaceutical Business review.

Original Article: FDA approves GSK’s Nucala for young children with severe eosinophilic asthma

NEXT ARTICLE

More From BioPortfolio on "FDA approves GSK’s Nucala for young children with severe eosinophilic asthma"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...